Stocks and InvestingStocks and Investing
Fri, July 6, 2018
Thu, July 5, 2018
Tue, July 3, 2018
Mon, July 2, 2018
Fri, June 29, 2018
Thu, June 28, 2018
Wed, June 27, 2018
Tue, June 26, 2018
Mon, June 25, 2018
Fri, June 22, 2018
Thu, June 21, 2018
Wed, June 20, 2018

Joseph Schwartz Maintained (SRPT) at Buy with Increased Target to $196 on, Jun 20th, 2018


Published on 2024-10-26 06:15:47 - WOPRAI, Joseph Schwartz
  Print publication without navigation


Joseph Schwartz of Leerink Swann, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $121 to $196 on, Jun 20th, 2018.

Joseph has made no other calls on SRPT in the last 4 months.



There are 6 other peers that have a rating on SRPT. Out of the 6 peers that are also analyzing SRPT, 1 agrees with Joseph's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Hartaj Singh of "Oppenheimer" Downgraded from Buy to Hold on, Friday, May 4th, 2018


These are the ratings of the 5 analyists that currently disagree with Joseph


  • Debjit Chattopadhyay of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $267 on, Tuesday, June 19th, 2018
  • Yun Zhong of "BTIG" Initiated at Strong Buy and Held Target at $120 on, Friday, June 15th, 2018
  • Gena Wang of "Barclays" Upgraded from Hold to Buy on, Friday, May 11th, 2018
  • Alethia Young of "Credit Suisse" Maintained at Buy with Decreased Target to $92 on, Friday, May 4th, 2018
  • Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $95 on, Wednesday, March 14th, 2018